What You Need to Know about Hereditary Uterine and Ovarian Cancer Syndromes
This activity has been archived and credit is no longer available.
In this presentation, Dr. Georgiann Garza reviews hereditary uterine and ovarian cancer syndromes, as well as the relevant genetic information, and Dr. Claire Hoppenot discusses prevention, screening, and treatment options of these syndromes.
This Hematology and Oncology Grand Rounds session took place on Friday, April 16, 2021 at 1:30 P.M.
Activity Information
This activity has been archived and credit is no longer available.
Needs Statement
Hematologist-oncologists, radiation oncologists, surgeons, other medical specialists, basic and translational research scientists, residents, fellows, and medical students need to be regularly updated on advances in the diagnosis and management of patients with hematologic disorders and related malignancies. The series aims to broaden the knowledge base of learners in these topic areas and improve their competencies to enhance the patient care experience and outcomes.
Educational Objectives
At the conclusion of the session, the participants should be able to:
- Outline the most common genetic mutations associated with uterine and ovarian cancer.
- Describe how to select patients for genetic testing.
- Examine screening strategies for women at risk of uterine and ovarian cancer and their risks and benefits.
- Discuss preventative measures for women at risk of uterine and ovarian cancer.
- Summarize treatment implications for women with genetic mutations.
Target Audience
Professional Categories
- Physicians
- Medical Students
- Fellows
- Residents
- Other Health Professionals
Specialties
- Family and Community Medicine
- Internal Medicine
- Medical Genetics and Genomics
- Obstetrics and Gynecology
- Oncology
Interest Groups
Accreditation/Credit Designation
Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Baylor College of Medicine designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Activity Director
Disclosure Policy
Baylor College of Medicine (BCM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians. BCM is committed to sponsoring CE activities that are scientifically based, accurate, current, and objectively presented.
In accordance with the ACCME Standards for Commercial Support, BCM has implemented a mechanism requiring everyone in a position to control the content of an educational activity (i.e., directors, planning committee members, faculty) to disclose any relevant financial relationships with commercial interests (drug/device companies) and manage/resolve any conflicts of interest prior to the activity. Individuals must disclose to participants the existence or non-existence of financial relationships at the time of the activity or within 24 months prior.
In addition, BCM has requested activity faculty/presenters to disclose to participants any unlabeled use or investigational use of pharmaceutical/device products; to use scientific or generic names (not trade names) in referring to products; and, if necessary to use a trade name, to use the names of similar products or those within a class. Faculty/presenters have also been requested to adhere to the ACCME's validation of clinical content statements.
BCM does not view the existence of financial relationships with commercial interests as implying bias or decreasing the value of a presentation. It is up to participants to determine whether the relationships influence the activity faculty with regard to exposition or conclusions. If at any time during this activity you feel that there has been commercial/promotional bias, notify the Activity Director or Activity Coordinator. Please answer the questions about balance and objectivity in the activity evaluation candidly.
All of the relevant financial relationships listed for these individuals have been mitigated.
Disclosures
The following individual(s) has/have reported financial or other relationship(s) with commercial entities whose products/services may relate to the educational content of this activity:
Presenters
-
-
Claire Marie Violaine Hoppenot, MD
Assistant Professor
Baylor College of Medicine
Disclosure:
Nothing to disclose.
Activity Director
-
Tannaz Armaghany, M.D.
Assistant Professor
Baylor College of Medicine
Disclosure:
Nothing to disclose.
Planning Committee Members
-
Tannaz Armaghany, M.D.
Assistant Professor
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
Salma Kaochar, M.D.
Assistant Professor
Baylor College of Medicine
Disclosure:
- Research Support: FGH Biotech; Systems Oncology
- Consultancy: FGH Biotech
- Board Membership: Translational Oncology
-
Daniel Y. Wang, M.D.
Assistant Professor
Baylor College of Medicine, Dan L. Duncan Comprehensive Cancer Center
Disclosure:
- Advisory Committee Membership: Regeneron; Sanofi-Genzyme
Health Topics
Presenters: